Stanford Abuses Spur Action On Curtailing Indirect Costs

Revelations of the school's squandeing of funds have overwhelmed those who until now had managed to avert arbitrary caps WASHINGTON--The political fallout from Stanford University's questionable use of overhead charges for its federally funded research projects appears likely to achieve what a decade of pressure from the White House could not do: place a cap on how much universities can spend on the administrative portion of their indirect costs. Welcome news for scientists is that such a ca

Written byJeffrey Mervis
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

WASHINGTON--The political fallout from Stanford University's questionable use of overhead charges for its federally funded research projects appears likely to achieve what a decade of pressure from the White House could not do: place a cap on how much universities can spend on the administrative portion of their indirect costs.

Welcome news for scientists is that such a cap would, in theory, free up an estimated $100 million or more that the government could then plow into greater support for research. At the same time, the imposition of a cap would signal a serious defeat for lobbyists representing the research-intensive universities where many of those scientists work.

Administrators at those universities have opposed past attempts to impose such a cap on the grounds that their institutions need full reimbursement of indirect costs to afford the laboratories, buildings, and support facilities required by today's research teams. Without such funds, they say, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies